VGXI Partner IMM Announces $12M NIH Grant to Support Phase 1 Clinical Trial of a DNA Vaccine for the Prevention of Alzheimer's Disease
The Woodlands, TX (PRWEB) March 30, 2022 -- VGXI, Inc., an industry recognized contract developer and manufacturing organization (CDMO) for nucleic acid
Source: prweb.com